Showing 701 - 720 results of 15,212 for search '(( 50 ((teer decrease) OR (mean decrease)) ) OR ( 5 ((point decrease) OR (nn decrease)) ))', query time: 0.69s Refine Results
  1. 701
  2. 702

    DataSheet1_Capsaicin suppresses ciliary function, while inducing permeability in bronchial epithelial cell cultures of COPD patients.docx by Halil Ibrahim Toy (10533263)

    Published 2022
    “…Formoterol significantly prevented decreases in CBF induced by capsaicin. Higher concentrations of capsaicin (250-500 μM) significantly reduced TEER of BECs from nonsmokers (T2-T24 h), smokers (T24 h) and COPD patients (T2 and T24 h), which was partially prevented by roflumilast. …”
  3. 703
  4. 704

    Lowering Melting Points in Asymmetrically Substituted Salen-Copper(II) Complexes Exhibiting Mesomorphic Behavior. Structure of the Mesogen Cu(5-hexyloxySalen) by Reinhard Paschke (553784)

    Published 2002
    “…In comparison with their symmetrical analogues, unsymmetrically substituted Cu−Salen complexes show mesophases with lowered melting points. For terminally substituted complexes, symmetrical ones (R<sup>1</sup> = R<sup>2</sup>) have only an S<sub>A</sub> phase, while for unsymmetrical alkoxy substitution a monotropic S<sub>E</sub> phase occurs and the melting temperature decreases with no loss in mesophase stability. …”
  5. 705

    Lowering Melting Points in Asymmetrically Substituted Salen-Copper(II) Complexes Exhibiting Mesomorphic Behavior. Structure of the Mesogen Cu(5-hexyloxySalen) by Reinhard Paschke (553784)

    Published 2002
    “…In comparison with their symmetrical analogues, unsymmetrically substituted Cu−Salen complexes show mesophases with lowered melting points. For terminally substituted complexes, symmetrical ones (R<sup>1</sup> = R<sup>2</sup>) have only an S<sub>A</sub> phase, while for unsymmetrical alkoxy substitution a monotropic S<sub>E</sub> phase occurs and the melting temperature decreases with no loss in mesophase stability. …”
  6. 706
  7. 707
  8. 708

    Fig 3 - by Jan Maleček (17396660)

    Published 2023
    Subjects:
  9. 709

    Fig 7 - by Jan Maleček (17396660)

    Published 2023
    Subjects:
  10. 710

    Fig 4 - by Jan Maleček (17396660)

    Published 2023
    Subjects:
  11. 711
  12. 712
  13. 713
  14. 714
  15. 715
  16. 716

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  17. 717

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  18. 718
  19. 719

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…(<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  20. 720

    Basic characteristics of the studies included. by Renáta Kiss-Miki (20760127)

    Published 2025
    “…Survival and six major types of side effects were assessed based on data in the articles and reported using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Heterogeneity was assessed using Higgins and Thompson’s I<sup>2</sup> statistics.…”